Updated Survival Outcomes From KEYNOTE-716 Support Use of Pembrolizumab in Stage IIB / IIC Melanoma

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • Key Points:
    • In patients with stage IIB / IIC melanoma:
      • Adjuvant pembrolizumab continued to demonstrate significant improvements over placebo in DMFS and RFS:
        • After a median follow-up of 39.4 months
    • Whereas an earlier analysis suggested that there may be a lesser benefit with pembrolizumab in patients with stage IIC disease:
      • This was not observed with additional follow-up
    • The 3-year RFS rates were:
      • 76.2% with pembrolizumab and 63.4% with placebo
    • In patients with stage IIB / IIC melanoma, adjuvant pembrolizumab provides a:
      • 41% reduction in the risk of distant metastasis or death
      • 38% reduction in the risk of recurrence or death:
        • According to an update from the KEYNOTE-716 trial presented at the 2023 ASCO Annual Meeting
  • KEYNOTE-716:
    • Was the first study to demonstrate a benefit for relapse-free survival [RFS] as well as distant metastasis-free survival [DMFS]:
      • Using anti–PD-1 immunotherapy (pembrolizumab) in patients with high-risk, non-nodal, stage IIB / IIC melanoma:
        • This updated analysis support[s] the durability of these findings over time
    • After a median follow-up of 39.4 months:
      • Adjuvant pembrolizumab continued to demonstrate significant improvements over placebo in DMFS (HR 0.59, 95% CI [0.44, 0.79]) and RFS (HR 0.62, 95% CI [0.49, 0.79]), consistent with prior reports
    • The investigators concluded that the results of this analysis support the use of pembrolizumab as adjuvant therapy in patients with resected stage IIB or IIC melanoma:
      • The effect of adjuvant anti–PD-1 antibodies is similar across stages of melanoma from stage IIB through stage IV resected disease
  • Having therapeutic options now validated in this setting is a big step forward for our patients and that the results of this final DMFS analysis confirm the important benefit observed in the previous DMFS report and further consolidate the role of pembrolizumab in this setting
#Arrangoiz #CancerSurgeon #HeadandNeckSurgeon #SurgicalOncologist #Melanoma #SkinCancer #MountSinaiMedicalCenter #MSMC #Miami #Mexico
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment